On Tuesday, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) opened higher 1.92% from the last session, before settling in for the closing price of $48.51. Price fluctuations for TARS have ranged from $20.08 to $57.28 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 172.29%. Company’s average yearly earnings per share was noted 54.38% at the time writing. With a float of $35.81 million, this company’s outstanding shares have now reached $38.35 million.
Let’s determine the extent of company efficiency that accounts for 323 employees. In terms of profitability, gross margin is 92.99%, operating margin of -65.9%, and the pretax margin is -63.16%.
Tarsus Pharmaceuticals Inc (TARS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Tarsus Pharmaceuticals Inc is 13.92%, while institutional ownership is 94.66%. The most recent insider transaction that took place on Mar 24 ’25, was worth 300,000. In this transaction President/CEO and Board Chair of this company sold 6,000 shares at a rate of $50.00, taking the stock ownership to the 824,106 shares. Before that another transaction happened on Mar 24 ’25, when Company’s Officer proposed sale 6,000 for $50.00, making the entire transaction worth $300,000.
Tarsus Pharmaceuticals Inc (TARS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 54.38% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
Check out the current performance indicators for Tarsus Pharmaceuticals Inc (TARS). In the past quarter, the stock posted a quick ratio of 4.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach 1.31 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Looking closely at Tarsus Pharmaceuticals Inc (NASDAQ: TARS), its last 5-days average volume was 0.49 million, which is a drop from its year-to-date volume of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 87.57%. Additionally, its Average True Range was 2.95.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 53.61%, which indicates a significant decrease from 77.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.97% in the past 14 days, which was higher than the 52.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.98, while its 200-day Moving Average is $41.53. However, in the short run, Tarsus Pharmaceuticals Inc’s stock first resistance to watch stands at $50.02. Second resistance stands at $50.61. The third major resistance level sits at $51.44. If the price goes on to break the first support level at $48.60, it is likely to go to the next support level at $47.77. Now, if the price goes above the second support level, the third support stands at $47.18.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
There are currently 38,377K shares outstanding in the company with a market cap of 2.06 billion. Presently, the company’s annual sales total 182,950 K according to its annual income of -115,550 K. Last quarter, the company’s sales amounted to 66,410 K and its income totaled -23,110 K.
